Business Wire·Nov 9, 2026, 8:00 AM ET

Delcath Systems Reports Third Quarter 2026 Results and Business Highlights

DCTH

Delcath Systems raised its 2026 full-year revenue guidance to a range of $115 million to $117 million.
Third quarter 2026 total revenue reached $35.1 million, up from $20.6 million in the same period of 2025.
HEPZATO KIT revenue was $32.7 million in Q3 2026, representing approximately 72% growth compared to the prior year quarter.
CHEMOSAT revenue totaled $2.4 million in Q3 2026, compared to $1.3 million in Q3 2025.
Gross margins for the quarter were 89%, an increase from 87% in the third quarter of 2025.
Net income for Q3 2026 was $7.0 million, compared to $0.8 million in the prior year period.
Non-GAAP adjusted EBITDA for the quarter was $11.5 million, up from $5.3 million in Q3 2025.
Cash provided by operations in the quarter was $8.2 million, compared to $4.8 million in the prior year quarter.
As of September 30, 2026, the company held $104.3 million in cash & investments with no debt.
The company currently operates 33 active treatment centers.
The global Phase 2 DELUMA trial for HEPZATO in breast cancer dosed its first patient on July 9, 2026, at the European Institute of Oncology in Milan.
The DELUMA trial is designed to enroll approximately 90 patients at over 20 U.S. & European sites.
Research & development expenses for Q3 2026 were $11.0 million, driven by increased clinical headcount & trial activity.
Selling, general, & administrative expenses for Q3 2026 were $13.1 million, due to continued commercial expansion.
The company plans an IND submission for cholangiocarcinoma in early 2027.
Pending FDA agreement, preclinical development of an oxaliplatin-based PHP product is targeted for completion by mid-2027.
Full-year 2026 gross margins are projected to range between 87% & 89%.
Full-year 2026 guidance includes positive adjusted EBITDA.
A conference call to discuss results is scheduled for November 9, 2026, at 8:30 a.m. Eastern Time.